Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Food Supplement for Longevity

15. juni 2026 opdateret af: Sam Treadway

An Open Label Study to Assess the Effect of a Food Supplement on Markers of Cellular Ageing and Longevity

As we age, the cells in our body gradually lose their ability to produce energy efficiently and repair damage. This process, known as cellular ageing, is linked to lower levels of a molecule called Nicotinamide Adenine Dinucleotide (NAD⁺), which is essential for energy production and maintaining healthy cell function. Other factors, such as reduced antioxidant capacity and mitochondrial decline, also contribute to ageing.

This study will explore whether a daily food supplement, taken for one month, can improve markers of cellular health in adults aged 35 and over. Thrive⁺ contains ingredients that may support energy metabolism and antioxidant defences, including compounds that boost NAD⁺ levels and Coenzyme Q10 (CoQ10), which helps cells produce energy. It also includes resveratrol, a plant compound thought to promote healthy ageing.

The research will take place at The Functional Gut Clinic in Manchester and will involve 15 healthy volunteers. Participants will attend two clinic visits: one at the start and one after 30 days of supplementation. At each visit, they will have blood tests, blood pressure and heart rhythm checks, a simple grip strength test, and complete short questionnaires on mood and wellbeing. Women of childbearing potential will also have a pregnancy test. The supplement will be taken as one capsule per day for 30 days.

The main question is whether the supplement increases NAD⁺ levels in the blood. We will also look at other markers, such as antioxidant status, inflammation, and physical measures like grip strength. The study aims to provide insight into whether supplementation can support healthy ageing in everyday life.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

18

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  1. Participant has provided written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.
  2. Participant has no significant medical diagnosis (health individuals)
  3. Participant takes no regular prescription medication
  4. Participant is not undertaking any restrictive diet (e.g. Carnivore, Low FODMAP)
  5. Participant agrees to adhere to guidance on fortified food intake for the duration of the study
  6. Participant is a male or non-pregnant female and is ≥35 years of age
  7. If WOCBP participant is willing to adhere to one of the following methods of contraception i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) iv) Hysterectomy v) Vasectomised partner vi) Sexual abstinence (if it is in line with your preferred and usual lifestyle).
  8. Participant can communicate well with the Investigator and to comply with the requirements for the entire study.
  9. Participant has a body mass index (BMI) of 18.5 - 39.9kg/m2 (bounds included).

Exclusion Criteria:

  1. Participant has consumed nutritional supplement, that in the opinion of the investigator may affect any of the study primary or secondary endpoints, in the past 3 months
  2. Diagnosis of any current medical condition that requires regular prescription medication or at the discretion of the investigator may affect study endpoints
  3. Participated in a trial of an investigational medical product or medical device in the last 28 days.
  4. Females who report to be pregnant or lactating
  5. Unwilling to maintain a stable diet for the duration of the trial.
  6. Unwilling to consume <5 portions per week fortified food per week
  7. History of drug or alcohol abuse
  8. Alcohol use >2 standard servings/day
  9. Being in the opinion of the investigator unsuitable, in the circumstance where patient safety of scientific value of the study may be affected i.e. unable to swallow capsules, phobia to needles, significant travel that would affect adhereance study participation etc
  10. Hypersensitivity to any component of the supplement
  11. Previously identified niacin deficiency
  12. Participant is involved in this study as an Investigator, sub-Investigator, study coordinator or other delegated study team members.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Longevity supplement
This is a single arm study, with the a participants receiving the active supplement. Supplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily.
Kosttilskud: Longevity supplement
Supplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in whole blood nicotinamide adenine dinucleotide (NAD+)
Tidsramme: 30 days
Change in whole blood NAD+ measured using Liquid chromatography mass spectrometry. Changes measured from baseline (pre supplement) to end of study (30 days of supplementation). measured in micrograms per millilitre.
30 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in plasma NAD+ metabolites
Tidsramme: 30 days
Changes in plasma NAD+ metabolites. These include changes in Nicotinamide (NAM) and 1-Methylnicotinamide. These are both measures in milligrams (mg) using Liquid chromatography mass spectrometry. Changes to be measured from baseline to end of study.
30 days
Change in total coenzyme Q10 (CoQ10)
Tidsramme: 30 days
Changes in plasma coenzyme Q10. This is measured in micrograms (ug) using colourimetry. Changes to be measured from baseline to end of study.
30 days
Change in standard haematology and biochemistry blood panels
Tidsramme: 30 days
Changes in haematology and biochemistry blood panels. Changes till be assessed by a study doctor and assigned any clinical significance. Any clinical significant findings will be recorded as an adverse event. Changes will be measured from baseline to end of study.
30 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Sam Treadway

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. marts 2026

Primær færdiggørelse (Faktiske)

12. juni 2026

Studieafslutning (Anslået)

1. august 2026

Datoer for studieregistrering

Først indsendt

15. juni 2026

Først indsendt, der opfyldte QC-kriterier

15. juni 2026

Først opslået (Faktiske)

22. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • FGC-26-03

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Sund voksen

Kliniske forsøg med Longevity supplement

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Jordan

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner